For over 30 years, Guthrie has been conducting cardiology clinical trials.   

Local access to leading-edge research

As a Guthrie patient you’ll have the unique opportunity to participate in clinical research trials that involve new treatments for atrial fibrillation, congestive heart failure, lipid disorders, heart attack and many more cardiology disease states.

Clinical trials

Clinical trials provide opportunities to evaluate the effectiveness of new ways to prevent, detect and treat cardiovascular disease. All FDA-approved medications and devices must prove effectiveness through a clinical trial.  Your individual participation will help advance new medical therapies for all patients. 

As a result, you receive excellent care locally from the Guthrie cardiology team, while still being able to access cutting-edge therapies offered in large university settings and metropolitan areas. Cardiology trials might involve preventive measures and/or treatments, experimental surgical techniques (stents), or devices (pacemakers, defibrillators), and/or new medicines. Your physician can present you with options and help you determine whether a clinical trial is right for you. 

Most clinical trials offered at Guthrie are phase two or phase three studies that measure safety and efficacy (whether the investigational treatment benefits a specific group of patients).

We work with multiple labs, pharmaceutical groups, and biotech companies to offer you the chance to get innovative treatments and novel therapies, and to assist with the future of cardiology care.  
 

Title: A021806, A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator:

Poulose MD, Joyson

Sponsors: National Cancer Institute
Details (Identifier #): NCT04340141
Title: A151216 ALCHEMIST, Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator:

Lash MD, Bradley

Sponsors: ALLIANCE
Details (Identifier #): NCT02194738
Title: ALLIANCE A222004:
A RANDOMIZED PHASE III TRIAL OF OLANZAPINE VERSUS MEGESTROL ACETATE FOR CANCER-ASSOCIATED ANOREXIA
Department: Oncology
Diagnosis: Not applicable
Principal Investigator:

Poulose MD, Joyson

Sponsors: ALLIANCE
Title: CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
Department: Oncology
Diagnosis: Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Astra Zeneca Pharmaceutical, LP
Details (Identifier #): NCT05774951
Title: CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator:

Poulose MD, Joyson

Sponsors: Astra Zeneca Pharmaceutical, LP
Details (Identifier #): NCT04964934
Title: EA6141, Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Department: Oncology
Diagnosis: Melanoma
Principal Investigator:

Lash MD, Bradley

Sponsors: ECOG-ACRIN Cancer Research Group
Details (Identifier #): NCT02339571
Title: ICECAP - Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients
Department: Emergency Medicine
Diagnosis: Cardiac - Miscellaneous
Principal Investigator:

Rittenberger MD, Jon

Sponsors: SIREN
Details (Identifier #): NCT04217551
Title: Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trial
Department: Oncology
Diagnosis: Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: ECOG-ACRIN Cancer Research Group
Details (Identifier #): NCT05710328
Title: LIBREXIA-AF A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Principal Investigator:

Kaluski MD, Edo

Sponsors: Janssen Research & Development, LLC
Details (Identifier #): NCT05757869
Title: Limited access protocol for the use of oral cisapride in the treatment of refractory gastroesophageal reflux disease and other gastrointestinal motility disorders. CIS-USA-154
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator:

McDonald M.D., Thomas

Sponsors: Janssen Scientific Affairs, LLC
Details (Identifier #): none
Showing 11-20 of 40 Results